{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:03Z","timestamp":1787664243684,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The FIGO scoring system is a well-established method for classifying patients with gestational trophoblastic neoplasia (GTN) worldwide, and the Japanese scoring system is widely employed in Japan. This study aimed to evaluate the clinical outcomes of de-escalated chemotherapy in patients with high-risk GTN, classified as \u201cclinical invasive mole\u201d according to the Japanese scoring system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 268 patients with GTN who received initial treatment at Nagoya University Hospital between 1991 and 2023. All patients were assessed using the FIGO and Japanese scoring systems, and treatment strategies were determined primarily based on histopathological diagnosis and subsequently guided by the Japanese scoring system. Clinical features and treatment outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 268 patients, 49 were classified as having high-risk GTN. All patients with FIGO scores of\u2009\u2265\u20099 were classified as \u201cclinical choriocarcinoma\u201d by the Japanese scoring system. In contrast, 17 patients with FIGO scores of 7\u20138 were divided into the invasive mole group (n\u2009=\u20097) and the choriocarcinoma group (n\u2009=\u200910). All patients in the invasive mole group received de-escalated chemotherapy and achieved complete remission. The proportions of patients with age\u2009\u2265\u200940\u00a0years (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046), antecedent hydatidiform mole (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021), shorter interval from index pregnancy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), and larger tumor size (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) were significantly higher in the invasive mole group than in the choriocarcinoma group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>De-escalated chemotherapy may be feasible for select patients with FIGO scores of 7\u20138, and further refinement of risk stratification is warranted to avoid overtreatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03105-z","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:50:22Z","timestamp":1782219022000},"page":"1960-1965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical experience with de-escalated chemotherapy for a subset of high-risk gestational trophoblastic neoplasia at a single institution"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-4872","authenticated-orcid":false,"given":"Kosuke","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3860-5548","authenticated-orcid":false,"given":"Taito","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9065-2059","authenticated-orcid":false,"given":"Mari","family":"Shirasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9209-7488","authenticated-orcid":false,"given":"Yuko","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0517-5091","authenticated-orcid":false,"given":"Eiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4546-9606","authenticated-orcid":false,"given":"Kaoru","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-1825","authenticated-orcid":false,"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"1","key":"3105_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000321","volume":"1","author":"CM Joyce","year":"2022","unstructured":"Joyce CM, Fitzgerald B, McCarthy TV et al (2022) Advances in the diagnosis and early management of gestational trophoblastic disease. BMJ Med 1(1):e000321. https:\/\/doi.org\/10.1136\/bmjmed-2022-000321","journal-title":"BMJ Med"},{"issue":"2","key":"3105_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/aog.0000000000004240","volume":"137","author":"JT Soper","year":"2021","unstructured":"Soper JT (2021) Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol 137(2):355\u2013370. https:\/\/doi.org\/10.1097\/aog.0000000000004240","journal-title":"Obstet Gynecol"},{"issue":"Suppl 1","key":"3105_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ijgo.70275","volume":"171","author":"HYS Ngan","year":"2025","unstructured":"Ngan HYS, Seckl MJ, Berkowitz RS et al (2025) Diagnosis and management of gestational trophoblastic disease: 2025 update. Int J Gynaecol Obstet 171(Suppl 1):78\u201386. https:\/\/doi.org\/10.1002\/ijgo.70275","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"3105_CR4","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2022.33.e72","volume":"33","author":"E Yamamoto","year":"2022","unstructured":"Yamamoto E, Nishino K, Niimi K et al (2022) Epidemiologic study on gestational trophoblastic diseases in Japan. J Gynecol Oncol 33(6):e72. https:\/\/doi.org\/10.3802\/jgo.2022.33.e72","journal-title":"J Gynecol Oncol"},{"issue":"Suppl A","key":"3105_CR5","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1053\/plac.2002.0933","volume":"24","author":"S Sasaki","year":"2003","unstructured":"Sasaki S (2003) Management of gestational trophoblastic diseases in Japan\u2013a review. Placenta 24(Suppl A):S28-32. https:\/\/doi.org\/10.1053\/plac.2002.0933","journal-title":"Placenta"},{"issue":"18","key":"3105_CR6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1200\/jco-24-02326","volume":"43","author":"C Lok","year":"2025","unstructured":"Lok C, van Trommel N, Braicu EI et al (2025) Practical guidelines for the treatment of gestational trophoblastic disease: collaboration of the European organisation for the treatment of trophoblastic disease (EOTTD)-European society of gynaecologic oncology (ESGO)-gynecologic cancer intergroup (GCIG)-international society for the study of trophoblastic diseases (ISSTD). J Clin Oncol 43(18):2119\u20132128. https:\/\/doi.org\/10.1200\/jco-24-02326","journal-title":"J Clin Oncol"},{"issue":"9742","key":"3105_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/s0140-6736(10)60280-2","volume":"376","author":"MJ Seckl","year":"2010","unstructured":"Seckl MJ, Sebire NJ, Berkowitz RS (2010) Gestational trophoblastic disease. Lancet 376(9742):717\u2013729. https:\/\/doi.org\/10.1016\/s0140-6736(10)60280-2","journal-title":"Lancet"},{"issue":"1","key":"3105_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1006\/gyno.2000.5813","volume":"78","author":"H Matsui","year":"2000","unstructured":"Matsui H, Suzuka K, Iitsuka Y et al (2000) Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 78(1):28\u201331. https:\/\/doi.org\/10.1006\/gyno.2000.5813","journal-title":"Gynecol Oncol"},{"issue":"3","key":"3105_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41416-022-01809-3","volume":"127","author":"M Ji","year":"2022","unstructured":"Ji M, Jiang S, Zhao J et al (2022) Efficacies of FAEV and EMA\/CO regimens as primary treatment for gestational trophoblastic neoplasia. Br J Cancer 127(3):524\u2013530. https:\/\/doi.org\/10.1038\/s41416-022-01809-3","journal-title":"Br J Cancer"},{"issue":"9","key":"3105_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/ijc.33403","volume":"148","author":"K Singh","year":"2021","unstructured":"Singh K, Gillett S, Ireson J et al (2021) M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin\/cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia. Int J Cancer 148(9):2335\u20132344. https:\/\/doi.org\/10.1002\/ijc.33403","journal-title":"Int J Cancer"},{"issue":"1","key":"3105_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10147-019-01540-9","volume":"25","author":"S Sato","year":"2020","unstructured":"Sato S, Yamamoto E, Niimi K et al (2020) The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia. Int J Clin Oncol 25(1):203\u2013209. https:\/\/doi.org\/10.1007\/s10147-019-01540-9","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"3105_CR12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/s1470-2045(21)00262-x","volume":"22","author":"A Braga","year":"2021","unstructured":"Braga A, Paiva G, Ghorani E et al (2021) Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol 22(8):1188\u20131198. https:\/\/doi.org\/10.1016\/s1470-2045(21)00262-x","journal-title":"Lancet Oncol"},{"issue":"6","key":"3105_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/humupd\/dmz027","volume":"25","author":"N Spears","year":"2019","unstructured":"Spears N, Lopes F, Stefansdottir A et al (2019) Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update 25(6):673\u2013693. https:\/\/doi.org\/10.1093\/humupd\/dmz027","journal-title":"Hum Reprod Update"},{"key":"3105_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156234","volume":"168","author":"C Bailly","year":"2023","unstructured":"Bailly C (2023) Etoposide: a rider on the cytokine storm. Cytokine 168:156234. https:\/\/doi.org\/10.1016\/j.cyto.2023.156234","journal-title":"Cytokine"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03105-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03105-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03105-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:52Z","timestamp":1787663332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03105-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3105"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03105-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}